mAbs

Article	Citations
Antibodies to watch in 2022	263
Antibodies to watch in 2021	249
Antibodies to watch in 2023	156
Targeting cancer with antibody-drug conjugates: Promises and challenges	102
BioPhi: A platform for antibody design, humanization, and humanness evaluation based on natural antibody repertoires and deep learning	81
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy	67
Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies	66
Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity	51
Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics	51
Developments and opportunities in continuous biopharmaceutical manufacturing	50
In silico proof of principle of machine learning-based antibody design at unconstrained scale	50
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro	49
Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins	45
Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns	45
Machine learning prediction of antibody aggregation and viscosity for high concentration formulation development of protein therapeutics	43
Coming together at the hinges: Therapeutic prospects of IgG3	40
Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods	39
Fc galactosylation follows consecutive reaction kinetics and enhances immunoglobulin G hexamerization for complement activation	38
Antibodies to watch in 2024	36
Identifying biophysical assays and in silico properties that enrich for slow clearance in clinical-stage therapeutic antibodies	36
Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries	35
Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors	35
Host cell protein profiling of commercial therapeutic protein drugs as a benchmark for monoclonal antibody-based therapeutic protein development	34
Calculation of therapeutic antibody viscosity with coarse-grained models, hydrodynamic calculations and machine learning-based parameters	34
One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics	33

Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies	33
A computational method for immune repertoire mining that identifies novel binders from different clonotypes, demonstrated by identifying anti-pertussis toxoid antibodies	33
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy	31
Assessing developability early in the discovery process for novel biologics	30
Impact of IgG subclass on molecular properties of monoclonal antibodies	29
Harnessing the potential of machine learning for advancing “Quality by Design” in biomanufacturing	29
Structure-based charge calculations for predicting isoelectric point, viscosity, clearance, and profiling antibody therapeutics	29
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays	29
Ab-Ligity: identifying sequence-dissimilar antibodies that bind to the same epitope	28
Glycoform-resolved pharmacokinetic studies in a rat model employing glycoengineered variants of a therapeutic monoclonal antibody	27
In vitro discovery of a human monoclonal antibody that neutralizes lethality of cobra snake venom	27
Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics	27
Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2	26
Exploration of the antibody–drug conjugate clinical landscape	26
Brain pharmacokinetics of anti-transferrin receptor antibody affinity variants in rats determined using microdialysis	26
Strategies for clinical dose optimization of T cell-engaging therapies in oncology	25
Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings	25
Highly sensitive detection of antibody nonspecific interactions using flow cytometry	25
Data mining patented antibody sequences	24
Evolution of phage display libraries for therapeutic antibody discovery	24
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis	24
Current strategies for detecting functional convergence across B-cell receptor repertoires	24
A non-clinical comparative study of IL-23 antibodies in psoriasis	23
Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRnin vitroandin vivo	23
A perspective toward mass spectrometry-based de novo sequencing of endogenous antibodies	23
Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV	23
A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations	23
Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches	23
Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies	21
Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors	21
Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities	21
Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries	21
Blueprint for antibody biologics developability	20
Full-length recombinant antibodies from Escherichia coli : production, characterization, effector function (Fc) engineering, and clinical evaluation	20
Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models	20
Versatile and rapid microfluidics-assisted antibody discovery	20
Predicting antibody binders and generating synthetic antibodies using deep learning	20
Challenges in antibody structure prediction	19
Protective antibodies against human parainfluenza virus type 3 infection	19
Enhancing the multi-attribute method through an automated and high-throughput sample preparation	19
Ensembles in solution as a new paradigm for antibody structure prediction and design	19
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters	19
In silico prediction of post-translational modifications in therapeutic antibodies	19
TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL	18
Physiologically Based Modeling to Predict Monoclonal Antibody Pharmacokinetics in Humans from in vitro Physiochemical Properties	18
Multi-attribute Raman spectroscopy (MARS) for monitoring product quality attributes in formulated monoclonal antibody therapeutics	18
Novel chimeric monoclonal antibodies that block fentanyl effects and alter fentanyl biodistribution in mice	18
Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?	18
Enzymatic glycan remodeling–metal free click (GlycoConnect™) provides homogenous antibody-drug conjugates with improved stability and therapeutic index without sequence engineering	17
Reduction of therapeutic antibody self-association using yeast-display selections and machine learning	17

Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells	17
Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer	17
Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans	17
A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention	16
Computational models for studying physical instabilities in high concentration biotherapeutic formulations	16
High concentration formulation developability approaches and considerations	15
Development of QSAR models for in silico screening of antibody solubility	15
Toward generalizable prediction of antibody thermostability using machine learning on sequence and structure features	15
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties	15
Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies	15
Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies	15
Rigid monoclonal antibodies improve detection of SARS-CoV-2 nucleocapsid protein	15
Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer	15
An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics	15
Differences in human IgG1 and IgG4 S228P monoclonal antibodies viscosity and self-interactions: Experimental assessment and computational predictions of domain interactions	15
Technical advancement and practical considerations of LC-MS/MS-based methods for host cell protein identification and quantitation to support process development	14
Mass spectrometry-based multi-attribute method in protein therapeutics product quality monitoring and quality control	14
International nonproprietary names for monoclonal antibodies: an evolving nomenclature system	14
Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names	14
Improved therapeutic index of an acidic pH-selective antibody	14
Off-target binding of an anti-amyloid beta monoclonal antibody to platelet factor 4 causes acute and chronic toxicity in cynomolgus monkeys	13
Animal- versus in vitro-derived antibodies: avoiding the extremes	13
Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors	13
Collecting antibodies and large molecule biomarkers in mouse interstitial brain fluid: a comparison of microdialysis and cerebral open flow microperfusion	13
Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment	13
A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351	13
Combining phage display with SMRTbell next-generation sequencing for the rapid discovery of functional scFv fragments	12
Functional GLP-1R antibodies identified from a synthetic GPCR-focused library demonstrate potent blood glucose control	12
An integrated approach for characterizing immunogenic responses toward a bispecific antibody	12
Stability of a high-concentration monoclonal antibody solution produced by liquid–liquid phase separation	12
The therapeutic potential of sialylated Fc domains of human IgG	12
Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants	12
The Fab portion of immunoglobulin G has sites in the CL domain that interact with Fc gamma receptor IIIa	12
Enhanced anti-angiogenetic effect of transferrin receptor-mediated delivery of VEGF-trap in a glioblastoma mouse model	12
Upstream cell culture process characterization and in-process control strategy development at pandemic speed	11
Mitochondrial membrane potential-enriched CHO host: a novel and powerful tool for improving biomanufacturing capability	11
Fc gamma receptor IIIb binding of individual antibody proteoforms resolved by affinity chromatography–mass spectrometry	11
Accurate determination of epitope for antibodies with unknown 3D structures	11
Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice	11
Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs	11
Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors	11
Physicochemical and biological impact of metal-catalyzed oxidation of IgG1 monoclonal antibodies and antibody-drug conjugates via reactive oxygen species	11
Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response	11
The proximity of the N- and C- termini of bovine knob domains enable engineering of target specificity into polypeptide chains	11
Non-targeted characterization of attributes affecting antibody-FcγRIIIa V158 (CD16a) binding via online affinity chromatography-mass spectrometry	11
The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein	11
Deciphering deamidation and isomerization in therapeutic proteins: Effect of neighboring residue	10
Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants	10
Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19	10
Insights into ultra-low affinity lipase-antibody noncovalent complex binding mechanisms	10
High-throughput profiling of antibody self-association in multiple formulation conditions by PEG stabilized self-interaction nanoparticle spectroscopy	10
Epitope mapping of anti-drug antibodies to a clinical candidate bispecific antibody	10
A machine learning strategy for the identification of key in silico descriptors and prediction models for IgG monoclonal antibody developability properties	10
Rational selection of building blocks for the assembly of bispecific antibodies	10
Quality comparability assessment of a SARS-CoV-2-neutralizing antibody across transient, mini-pool-derived and single-clone CHO cells	10
Reproducibility and flexibility of monoclonal antibody production with Nicotiana benthamiana	10
Deep mutational engineering of broadly-neutralizing nanobodies accommodating SARS-CoV-1 and 2 antigenic drift	9
Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL	9
Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrier	9
Phenotypic whole-cell screening identifies a protective carbohydrate epitope on Klebsiella pneumoniae	9
TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity	9
Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics	9
David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors	8
Structure-based engineering of a novel CD3ε-targeting antibody for reduced polyreactivity	8
Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies	8
Engineering death resistance in CHO cells for improved perfusion culture	8
A computational method for predicting the aggregation propensity of IgG1 and IgG4(P) mAbs in common storage buffers	8
Variable domain mutational analysis to probe the molecular mechanisms of high viscosity of an IgG 1 antibody	8
Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency	8
A window into the human immune system: comprehensive characterization of the complexity of antibody complementary-determining regions in functional antibodies	8
Development of T-cell engagers selective for cells co-expressing two antigens	8
Host cell protein detection gap risk mitigation: quantitative IAC-MS for ELISA antibody reagent coverage determination	8
NAb-seq: an accurate, rapid, and cost-effective method for antibody long-read sequencing in hybridoma cell lines and single B cells	8
Predictive modeling of concentration-dependent viscosity behavior of monoclonal antibody solutions using artificial neural networks	8
“Stapling” scFv for multispecific biotherapeutics of superior properties	8
SpyDisplay: A versatile phage display selection system using SpyTag/SpyCatcher technology	7
Agonistic nanobodies and antibodies to human VISTA	7
In-line product quality monitoring during biopharmaceutical manufacturing using computational Raman spectroscopy	7
A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3	7
Biparatopic antibodies: therapeutic applications and prospects	7

Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein	7
The impact of immunogenicity on therapeutic antibody pharmacokinetics: A preclinical evaluation of the effect of immune complex formation and antibody effector function on clearance	7
A platform-agnostic, function first-based antibody discovery strategy using plasmid-free mammalian expression of antibodies	7
Bispecific antibody target pair discovery by high-throughput phenotypic screening using in vitro combinatorial Fab libraries	7
Sensitive, homogeneous, and label-free protein-probe assay for antibody aggregation and thermal stability studies	7
Development of in silico models to predict viscosity and mouse clearance using a comprehensive analytical data set collected on 83 scaffold-consistent monoclonal antibodies	7
Targeting and pharmacology of an anti-IL13Rα2 antibody and antibody-drug conjugate in a melanoma xenograft model	7
Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition	7
Structural and functional characterization of a monoclonal antibody blocking TIGIT	7
Impact of IgG subclass on monoclonal antibody developability	7
An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy	7
Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework	6
The eIg technology to generate Ig-like bispecific antibodies	6
Extending the capabilities of intact-mass analyses to monoclonal immunoglobulins of the E-isotype (IgE)	6
Identification of critical chemical modifications by size exclusion chromatography of stressed antibody-target complexes with competitive binding	6
A glyco-engineering approach for site-specific conjugation to Fab glycans	6
Efficient production of bispecific antibody by FAST-Ig TM and its application to NXT007 for the treatment of hemophilia A	6
Epitope mapping of monoclonal antibodies: a comprehensive comparison of different technologies	6
Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors	6
CDR loop interactions can determine heavy and light chain pairing preferences in bispecific antibodies	6
Comprehensive engineering of a therapeutic neutralizing antibody targeting SARS-CoV-2 spike protein to neutralize escape variants	6
Generation of robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds: a comprehensive comparison of formats	6
Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies	6
Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models	6
In silico high throughput mutagenesis and screening of signal peptides to mitigate N-terminal heterogeneity of recombinant monoclonal antibodies	6
Suitability of transiently expressed antibodies for clinical studies: product quality consistency at different production scales	5
Interrogating heterogeneity of cysteine-engineered antibody-drug conjugates and antibody-oligonucleotide conjugates by capillary zone electrophoresis-mass spectrometry	5
Isolation and characterization of monoclonal antibodies against human carbonic anhydrase-IX	5
Kinetic analysis of ternary and binary binding modes of the bispecific antibody emicizumab	5
N-terminal selective conjugation method widens the therapeutic window of antibody–drug conjugates by improving tolerability and stability	5
Identification of critical chemical modifications and paratope mapping by size exclusion chromatography of stressed antibody-target complexes	5
Identification and characterization of an unexpected isomerization motif in CDRH2 that affects antibody activity	5
Therapeutic index improvement of antibody-drug conjugates	5
Combining random mutagenesis, structure-guided design and next-generation sequencing to mitigate polyreactivity of an anti-IL-21R antibody	5
Selection of target-binding proteins from the information of weakly enriched phage display libraries by deep sequencing and machine learning	5
Untargeted proteomics reveals upregulation of stress response pathways during CHO-based monoclonal antibody manufacturing process leading to disulfide bond reduction	5
Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering	5
Mechanistic insights into the rational design of masked antibodies	5
Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain	5
Challenges of non-clinical safety testing for biologics: A Report of the 9th BioSafe European Annual General Membership Meeting	5
Characterization of high-molecular weight by-products in the production of a trivalent bispecific 2+1 heterodimeric antibody	5
Identification of a CE-SDS shoulder peak as disulfide-linked fragments from common CH2 cleavages in IgGs and IgG-like bispecific antibodies	5
Clearance of therapeutic antibody glycoforms after subcutaneous and intravenous injection in a porcine model	5
Correlated analytical and functional evaluation of higher order structure perturbations from oxidation of NISTmAb	5